Hetero Labs Limited acquires Tarbis Farma in Spain

The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and seamless entry into the Retail, Hospital and Tender business channels in Spain.

Hyderabad: Hetero, one of India's generic pharmaceutical companies and producer of anti-retroviral drugs, recently announced that its European subsidiary Amarox Limited has acquired Tarbis Farma, S.L.U., a company operating in Spain from Grupo Ferrer Internacional, S.A.

Tarbis Farma comes with a robust product portfolio and an extensive marketing network with well-experienced personnel in Retail business across Spain.

The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and seamless entry into the Retail, Hospital and Tender business channels in Spain.

Mr A V Narasa Reddy, Executive Director of Hetero Labs Limited, stated that this acquisition fits very well with Hetero's growth strategy in EU giving Amarox a platform to reach out to the customers in a robust way with the present portfolio and Hetero's pipeline of products.

The buyer and seller were advised by Crowe and Deloitte respectively.